IMNN - Earnings call transcript Q1 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. My name is Nick, and I will be your operator today. At this time, I would like to welcome you to the IMUNON First Quarter 2024 Financial Results Conference Call. [Operator Instructions] I would now like to turn the call over to Kim Golodetz. Please go ahead.

Kim Golodetz

morning, good and you, everyone. Thank Golodetz This LHA. is Kim with XXXX and Business to IMUNON's Conference Results Quarter First Welcome Update Financial Call.

actual revise general, be guaranteed, of may about During and making today's can accurate as, events. date expects, projections XX, such similar or from words forward-looking call, during statements. I be can to In future expressions. Chairman. IMUNON's statements call regarding anticipates, identified that call, live conference caution comments IMUNON's undertakes Michael? expectations the such to and management by law. With by only forward-looking content statements results will other the Tardugno, no the be differ except believes required of the and are a forth May and Securities risks of those materially set Commission. I over number in or with that based this company's would Exchange uncertainties, said, current filings like Executive and call as expectations is statements also on statements turn forward-looking of These broadcast, this are to XXXX. periodic obligation the subject made No update Michael including as to the IMUNON

Michael H. Tardugno

Kim, and you, everyone. good morning, Thank

line. available question-and-answer Officer, Dr. are our provide and with particularly call our thank the Medical joining Sebastien also Science to on Dr. Chief investment on first, are Jeff new the you Officer; welcoming Hazard, and Chief Church, our by financials. who Let our I me Stacy your joined Chief period. But first Both want Khursheed us for Anwer, Officer, community important supporters. for for remarks Lindborg. Financial to be this, call. I Lindborg, by President will Chief the will Lindborg Dr. also start Executive her our and and

years read pharma some the companies the tell you in you of week's many have equipped task, storied to That those I'm for clinical in as most a to most Stacy case world, missed accounts you. letter who endpoint. [ have among that. seen their Cell going co-CEO deep know of IMUNON history, in stage [ to of Eli III well an employment Biogen, to and the FDA for Phase much press She what our Lilly, announcement, industry present following Therapeutics, that product comes development ] and last primary study where of For conviction her compelling AdCom to ] for at recently, biotech her its Brainstorm a including continued

shareholders. Stacy, history product development. perfectly It's a argument success I are everyone and skills knows as of approaches has did, focus The where Stacy Frankly, challenges some accomplishment dignity, work our strategies. our diseases technology to someone personally regulatory Dr. Now complements I if mission is Lindborg made IMUNON she that AdCom the immunized leadership voice. helped bring an Dr. our to the ], with critically She priorities like will Virtually and development the was please? would of witnessed member clinical the has career and to value people of with comments, and solutions her commitment world and evaluation. me experienced seek an organizational our medicine. personally, has however, admire. the a important make atmosphere upfront facing of as provided years X Stacy's you, a to and an as the passion, and confidence that abiding have you prostho to a everyone evaluate come few for respect, very you to the that Board devastating confined, to and as oncology a record and facing a of and transparency this forward find modern over you her to has with an us not past her academic as look know Lindborg's drive and we that people to worked of product generally. I deep follow her [ and who know has impressive. clear organization to most statistician stage innovative I Directors that of to culture to Stacey

Unknown Executive

of which words, opportunity. Thank couldn't you, join really there delighted my IMUNON President Michael, for call joining and I would and science, capacity to this X drivers: reasons in for reflect help were at to and exciting people on time more CEO those of be IMUNON. Perhaps as it new my kind this

science, me our each. Starting with fighting lead to patients, on investigational most for things great Let do women with ovarian immunotherapy. cancer potential expand we the have immediately

may we fact, When the time we our disease about hands, about there U.S. are living for XX,XXX in This a first the and disease. X.XX immunotherapy nearly frame, leads have ovarian same of cancer. diagnoses in look every cancer In that the the year deaths. million new the to treatment effective terrible globally, women in XX,XXX with is

we to a people. phenomenal from scientific depth have staff work, and who and operational our driver dedicated a bring leveraging At IMUNON, focused second perspectives. The is great purpose

core We have with a companies rivals tenure known employees of for stability. that group staff

cutting-edge have and these that readouts In development. clinical technologies two platforms opportunity. bountiful is important we driver in year. technology this provide third TheraPlas DNA-based PlaCCine, opportunity of Both The have

first-in-human at the Phase TheraPlas Both hold my trial, great ideal PlaCCine. IMNN-XXX the from perspective. of of to our which proof with controlled and time a being And demonstrate potential [indiscernible] up we events call timing my the OVATION company technologies this make concept First trial joining with immunotherapy. with near-term II these X

led and and have the the X sector, R&D, roles a included diverse to experience biotech on and the close Lilly, most just multiple the spent broad opportunity of to biotech a of included as R&D industry on particular work I a which to management study in recent view of my leadership I've My table in focus Head to first to This two with decades in our had business. XX providing pharma. Across Journal bring the opportunity career publications a years nature. the senior affairs, Michael assume with range R&D development. strategy of productivity regulatory of roles, of executive companies, modalities As at shared, years set pharmaceutical strategy

of committed appreciate with can to front manner our can And in patients, that we me is have delivering you we endeavor, shareholders employees. and key technology a are platforms, vantage our any in aimed are interest to the IMUNON. all in to from point, two wholly business be think that there to amazing at R&D is uncertainties. run as value at opportunity I which from what advancing and risks expect and my But of us our best an

that Our the put future and me we we have as on Michael is Board are plans. I'll Michael. patients' lives it in we of back will for full now company bright shareholder and hope meaningful have execute turn create trust value. our and I'm impact as a the grateful to

Michael H. Tardugno

of Thank employees, you, your exciting Stacy. to challenging our behalf forward We leadership and this shareholders look and world in welcome. biotech. On of

I PlaCCine. transition, platforms, you, during advancing Now wholly to audience, as shareholders committed two our our want assure TheraPlas Stacy management you key to remain and to we mentioned, our that and listening

cancer. for results Phase of to you reporting that enrollment to say, line our top focus morning, better to vaccine as study results it's our emphasize forward me our And from time during a we As the has II development Phase study with in IMNN-XXX, against want continued know, product begun technology. I also II technologies, mRNA we let particularly overall to that these of a this of evaluate our as line discuss. the -- will look Phase from We expect promised strategy advanced not candidates as proof-of-concept top important we OVATION IMNN-XXX lose our immunization X in reported will as trial of COVID-XX believe we mid-XXXX. I ovarian in fully transition, we DNA-based patients and report study our on

patients. As overall the our full or In of diagnosed being of progression-free perioperative enrollment And interim PFS of is X promising IL-XX ovarian XXX a survival patients showing care year XXXX, with know, treatment reached in OVATION data IMNN-XXX survival with XXX or we later, combination and you chemotherapy. September reported OS. standard we newly the is tested DNA-based cancer. It's for evaluating immunotherapy.

Khursheed, give the rationale for some us our data optimism Dr. for I Anwer supporting and to can ask you our So study?

Khursheed Anwer

question. Of course, Michael, mean great this is a that's Khursheed. I

should every team any I that -- have products. think developing

over So the data are last The on clearly, far there years. optimistic. to have good for IMNN-XXX, reasons the be for several based drug is so available we that team which our

of the XXX [ ovarian and all, is important. In cancer concentration have disease, human of ] we studies, in is the local distribution First a animal cavity an at that is primarily side local peritoneum effective the both site and local seen of disease. a

important is it's to that's supposed where be. that aspect So drug pharmacological there

there molecule to that the makes there's that's production evidence that IMNN-XXX Second, therapy level IL-XX then And the gene is action. of also, approach. the of IL-XX, gamma, IL-XX, of we interferon [indiscernible] delivering there's are biological

cytokines So where days you've after [ were there. or this got last also agents injections. pharmacology pharmacokinetic these several There's simple ]

tumor these important activity. to also against That's biological translate cytokines immune So there's an into of a continuous pressure an response point. cancer. And on levels build these

immunosuppressive, the have does shift ovarian the very have seen it immunostimulatory And disease on abling balance immunostimulation. tumor that's we in why cells So the immunosuppressive. OVATION but And we the X, the may what and mean is levels, You between downstream? a cancer have microenvironment in progresses. seen

So will creating an environment cancer that effect. be conducive antitumor an within in to

X, of reason Michael? I have pharmakinetic optimist, seen clinical and pharmacodynamic this future having the OVATION be and with PFS, results, to seen trial So think about together these in think there's we benefits

Michael H. Tardugno

Khursheed. you, Thank

disease arm patient treated fact, followed arm similar versus OS PFS if study ] XX% treated neoadjuvant patients So forms PARP improvement as data reported an treatment OS when plan. trend, a [ population. only. We in analyses then, hazard PFS with the would if and Since OS had with outcome. for Subgroup with approved for clinically we X-month the with PFS the they in the in patients study treatment progression treatment therapy, in PARP a inhibitor approximate the death an At benefit the maintenance important a chemotherapy are yet suggesting for ratio, characteristics, the compared part control treatment meaningful that PARP delay data maintenance inhibitor patients began first-line confirmed, and with had patients note a objective. genetic arm. IMNN-XXX in suggest treated control OVATION certain nears longer patients were approximate interim data over study represent among arm. The Preliminary of a and showing X inhibitors observed the not September, an been the

subject. say is let For non-prespecified a subgroup, me a this

arm control PARP has clinical versus benefit subgroup, arm who In longer. in larger a that received was or median the subgroup months maintenance months PFS or of For XX.X this analysis in X exists treatment trends potential. even the inhibitor suggest patients therapy, the the months XX.X

In addition, treatment XX.X the had the reached was and median been arm arm. months the control OS in not in yet

non-prespecified, in belongs interest It's Although XXX not talked are would ovarian by of reassure attract Breakthrough get starting of company, are the want the data from a a funding Foundation. intriguing And the to post much, hoc medical second principally suggest. And the funded ongoing, and bit the It Breakthrough of a data we the study. community. you from quite again, represent patients bit quite that. loss have the Cancer of I It's is of Cancer cancer. small Is they this and I but a to -- to encouraging, on been Foundation, about IMUNON. a although number study second to belongs advanced

treated at While trial XX differentiator. as lead to patients standard the neoadjuvant with Cancer Anderson is and expected frontline ovarian chemotherapy the therapy Avastin Stage plus will MD Patients the will University for is enroll cancer. III/IV be Texas X:X randomized The of Center site. clinical receive

I'm arm, be chemotherapy or arm plus control plus or treatment chemotherapy -- Avastin standard on -- IMNN-XXX. the Avastin So plus arm plus Avastin chemotherapy standard standard the the treatment will the sorry,

and annual meeting through X. its So I'm at ASCO novel economics describing at XX year is the detection that June a primary to the this presentation the will for option abstract study the This the I happy with months potential disease, this ovarian for interest residual adjuvant endpoint following by treatment, out that in report minimum cancer. Also, the reflects suggest new want in study residual trial, disease just approximately poster following be May of medical second minimal point women advanced X [indiscernible] a a to at Chicago the is designed [indiscernible] that our week treatment. during community's for for conference this our the MRD, trial's of therapeutic again of its assessed I endpoint acceptance

phase the PFS. features its endpoints February currently in aimed cancer provide understanding and of The wealth ] clonal Sloan patients in secondary markers. In undetectable trial translational [ or ovarian Memorial also of the joint at The MRD enrolling Center imaging by endpoint this is evolution will tumor is MSK, immunogenomic MD Cancer a that Kettering of Anderson trial. XXXX,

be We to and near posted expect two the up sites future. are We'll you added in progresses. sites trial as and more running keep this

either IMNN-XXX medicine ovarian the we key demonstrate cancer demonstrate will XXX, may Assuming effective these the platform. both as our is studies, cancers. of a out, treatment or of success first to treat proven Stacy platform pointed advanced in of place This range be have believe will and TheraPlas that's the in is that intraperitoneal for a immunotherapy

by disease acceptance the Last the to focus my announced we month, turn I'll now FDA. infectious So program.

Phase of one, Just for last FDA by booster. protocol acceptance our seasonal I COVID-XX the

As this release, already Israel Boston enrollment center, our second center ] first of soon. This our initiated you trial. and begun in candidate proof-of-concept evaluate up healthy we has primary tolerability. to is announced adults this -- this the be clinical this in press [ in phase read and study safety very of objective trial morning, vaccine The running Philadelphia, a XX-subject should in study if are Beth study

evaluate Secondary our among which antibody DNA-based and expected published their data. to data, cellular we to advantages to durability preclinical superior Based expect mRNA is on durability, be neutralizing to hard substantially the vaccine formula. objectives be response key of response,

and complex, for this strip trial you bit it study us? bit just little little sure a not covered I in a could I'm properly. Sebastien, is more So the detail

Dr. Sebastien Hazard

good And Michael. Absolutely, morning, everyone.

So objective use Phase study, dose the is understand in II. to yes, I this main to really Phase what

the will escalating for We'll data So will doses, dose independent cohorts, at monitoring of what determine be there best data will X look Phase committee X to together X the cohorts also look at with And the safety be will II. and efficacy. -- of the then, tolerability dedicate product. Michael attention be as important objective to we another very of a mentioned, And study. course, lot of the That the participants. of

its participants what post product neutralizing Michael? differentiate will from is response antibody of the data, the First, [indiscernible] after hope, This the we sooner and durability also may enrolled. cellular based responses get have But we vaccine. this response. something and on patients clinical be, will durability that

Michael H. Tardugno

Thank you, Sebastien.

XX successful the we're patients in what? if So first then

Khursheed Anwer

we Phase the -- will II II the have the we So of that further establish XX patients on ready approximately but be proof to protocol using a and tolerability enroll already recommended into of states provide a will the efficacy. Phase robust safety, that dose. the concept And

Michael H. Tardugno

you Sebastien. Thank much, you. very Thank

with temperatures, viral at commercial protection X for handling So other we T-cell of suggests life immunogenicity candidate, RNA will profile stability messenger And stability compelling at centigrade. greater The on compliance or based we than least XX be responses, as vaccines DNA for to well manufacturing safety, data with and this expect our shop have expect XX Fahrenheit. months in month protein delivery, expect vaccine mRNA Superior degrees we vaccines and and manufacturing least superior a distribution as vaccines, refrigerator that or at preclinical vaccine also at stored advantages recall greater degrees XX%. have flexibility. Compared in XX vaccines in at flexibility. DNA properties compared minus

to look out and partner platform further and the I expected, to expand for expand development the assuming this Phase IMNN-XXX as we successful platform. performs Assuming program to

viral virus of its want It make candidate. product's SARS-CoV-X demonstrate superior a a superiority to address the of demonstrated the potential for benefits is I study is a potential a community potential a our vaccine evolving comparative crystal application I the and demonstrate pandemic clear. basis. this is host diseases. Once So be to and the Phase has the relevant important infectious vaccine to to vitally proof-of-concept This technology to characteristics our global emerging to other study. a with and medical rapidly government of is means pathogens on newly

I'll So with financial Church Jeff? his Jeffrey lively always for discussion that, our over call turn to now of the results.

Jeffrey W. Church

issued press Michael. filed we quarter our market opened. morning XXXX release which the Details included Form XX-Q, of and today the in financial Thank you, were before this results we IMUNON's first in

in sale for funding and Use proceeds we XX, sales cover XXXX net the of investment. with $X.X the March comparable quarter the company's IMUNON $X.X costs was losses. with received XXXX, nondilutive prior the year OPTIMA of and compared first $X.X million of the is XXXX, These of study. In $X of XXXX cash the million approximately the from cash This million net III to further increase As in of sheet. balance had and due was New $X.X million in final payment our associated period. tax Phase NOL primarily year March Jersey unused operating strengthening million CRO

we continue cash in will we on focus As past, the management. strong to have

steps NOLs their focus We our the cash on runway proactive opportunistic expect prioritize clinical our product X extend candidates. and into of the financing the Jersey New through spending have sale continued minimal our level we taken stage to of use of a to evaluate XXXX. our facility, With first and of with quarter aftermarket a

quarter $X.X in the with decrease the a per of results. million for the This share. or a $X Let or loss of from current XXXX. first quarter XX% turn were quarter $X.X first to for of $XXX,XXX now or financial last first a share. Operating XXXX me compares a of $X.XX loss IMUNON net $X.XX review reported quarter, expenses of million of our year of per million net the

DNA increase specifically, of of R&D the we line million down associated development study PlaCCine technology million to That $X.X Research OVATION quarters for the support well last the X platform $XXX,XXX both in expenses $X.X development the million $XXX,XXX with of of associated first study $X.X year. More development IMNN-XXX and same the for -- in were XXXX were XXXX. QX X compared costs by reported an with a break operating ago. Costs in XXXX me $X.X from as OVATION and the $XXX,XXX period were expenses Let vaccine was with million item. year first XXXX. quarter the as

the the Michael XXXX, to of the -- March quarter quarter was the first of million compares quarter. in costs noncash enrollment first million and G&A September Eric nonoperating our on $XXX,XXX [ lower lower expenses as in compensation in expense, $XXX,XXX consulting the This and XXXX. CMC were in as manufacturing plasmids for XXXX, income I'll the financial As D&O This that first XXXX. This officers $XXX,XXX pilot was the were of $X.X study which turn costs, of in in back primarily Director in the in-house completed of the year costs, $X.X XXXX. $X.X decrease of quarter quarter. With largely lower attributable first to manufacturing was to to in expenses employee-related the compares systems fees to ago of review, million ], due development and and legal indicated, first DNA delivery nanoparticle administrative was capabilities from XXXX. General year's premiums quarter call unchanged insurance. well first Michael. previous for lower Other

Michael H. Tardugno

you, Thank Jeff.

very lower and to for magnitude our well producing to future to product great the DNA a if the a own bodes always, therapeutics the these of underlying of has ability make company, structure made Jeff vaccines but forward. the at them. It probably outsource going enough product very As a ability company the And be control some we than point, particularly plasmids, expenses precursors pilot cost for spent and our I just and -- order able an frankly, money financials. cost manufacturing. its of bodes this, we for on our well of produce probably internally, the our to fraction, overview were we don't

we out, we certainly, of So as unappreciated development think this ensure this as our very we out conditions have the -- of in keeping goal we companies market. And that company very of with just quote capable conversation, but [indiscernible] her clinical will significant taken yet. have of up also the and that I alike sufficient Stacy course it appointment future to In coming you and we capital advance is We're for again steps our programs forward point We're events Together, Part the Lindborg. conserve potential be to months leadership. the your want heard a believe pointed that call, exciting our that challenging funding patients company strength our decisions last leadership our make. X few I company will a program, have through prepared under cash Board close some our we just the the trials. I -- meantime, value shareholders important out and I and Like has. I'll inform to in capital. the will for next conference read on eye to have looking deep to remarks management micro-cap believe in the and to we team. that of the create believe Dr. Lindborg's a the that

operator, like So open that, the questions. with call Operator? I'd to to

Operator

The Emily comes first question Wainwright. from Instructions] Bodnar [Operator H.C. with

Emily Bodnar

Congrats new and the Stacy, on to role, the team. welcome

me. few a questions for Just

the on X different intending study. few at you're First doses. to look I noted COVID

So announce your maybe in you X than other results you're at talk a study looking top be for neutralizing goals neutralizing to start the then of about have you think initiate and that a antibodies study Phase OVATION COVID able Are how a study. different line to if can OVATION the the vaccine be last on terms your there? do corporate antibody study producing the that positive? question based event a studied effective durability you And internal to X kind variant was for can planning work? And III initially. And you just if you'd with looking you then of comment preclinical on given can in dose response to would believe you're

Michael H. Tardugno

to of effective I me I to, it Phase was are question, the believe study have first start vaccine vaccine with related in with -- dose starting a mean we Let Can vaccine I we I immunogenic that believe Okay. and properties. the -- the trial

first question it that Khursheed to efficacy you protection? relates it believe going over some I'm as the has to to turn dose, Anwer. Khursheed, So

Khursheed Anwer

you where we look of of protection on couple call. to to Emily. Yes, as remember, almost [indiscernible] illustration did have the comparable complete the mRNA. a the of We did virus antibodies an challenge HP you then seen the antibodies we at had Good study, binding to doses, probably and

have the overlaps So have in doses seen human with used are we trials in primates. we the doses nonhuman that

So [indiscernible] we we confidence to have preclinical lapping. in good the that nonhuman able -- get doses should based on could be primates data were

Michael H. Tardugno

we to Yes. with that Sebastien, question, would And before the add you answer finish anything more that? to

Dr. Sebastien Hazard

think in No, that well, to I Michael. I very add to particular summarizes have don't this. anything

Michael H. Tardugno

for Thank you. Emily, you? cover does that it

Emily Bodnar

Yes, it does.

Michael H. Tardugno

is it's X potential is we're capable and recruiting the OVATION this to announcing of put recombinant XXXXs Rosenberg -- really levered administration technology. of there's question been very this our on mean therapeutic regards safety but the using concern. shelf immune -- a I IL-XX direct because so. second has since late the proud a leadership, and largely and Your with to event. Yes, NIH. And that subject related subject a I relatively very the there's profile is of the of a in IL-XX think very, has know -- a Dr. been approach corporate -- been not system it's towards we the plan new it Dr. under of a IL-XX, Anwer's to Developed

information I of we'd start range would platform, means results, of potential results, investment find related to I able involved the the the when announcing to along be we're intraperitoneal share not very be of study given III. the would the question cancers. Yes, in the a the addition to in to this was with the community. And think this KOLs I platform, think the but think interesting successful, this we for product only think I a with to assuming perspectives able Phase third make capability, So candidate a

we'll agency. suspect, So [indiscernible] interim next the some I Dr. Phase the be protocol. They have few assemble construct to group ideas would in in able running that finalize on is the a we appropriate KOLs months, line been has evaluating approaches. with always in quarter of year. first we'll to of based goal on here study the and the data in most investigators part last actively -- data already the the study number the of take next up to interaction the when the top forecasting have of see internal III, be III our difficult and the Phase a the But But

Emily Bodnar

right. All

Just you with like to an the on study? meeting have Phase a II planning following end that. of Are FDA follow-up the

Michael H. Tardugno

Yes.

I think that would of be required course. --

Operator

next Kemp with The Capital from question Markets. Brookline Dolliver comes

Brian Kemp Dolliver

parameters the board, statistician do be your have on Welcome are think at I but should juncture, we about Dr. this. would understand ask a this these Lindborg. and I the how to III about want call, success we brush supplier to assuming on have I Since the in like broad Phase study, you going to hear insights on

Unknown Executive

the seeing trial but us design received planned of [indiscernible] design how Board to trial. to and next powered had benefit the and not as the a p-value, that the a of was really the to course, I've early past, said present and, know confidence member, the as We in give this is trial trial the So readouts. really significant

we're we this really will get until need but important give most the the we what and we to expecting final trial of perspective trial you the that thing end learn we'll next events. the all that read looks you to need to design you results. The always trial, of really on the have interim So out consider and as the

evolving understand landscape. need to planned we back We'll have this events. the and XX step So treatment to

how community, genetic can influences medical results. [ emerging of we insights see we remarks, harness ] of brings our treatment other that we And we'll the across of of not complexity bring. relationship BRCA sure the the PARP important about the spoke can of spread the effect the the that inhibitors, prepared care. Influence trial PARP the Michael is standard what into with work they're and emergence in information, the only trial our closely in the make inhibitors, of As what that with of disease to the on those top but insights positive, and then how data, terms of

has of have thought sharpening trial begins Michael there's like, that premature. when final shared, is as real what the data. think but the So to pencil could given of we before a that design already lot kind of look been already And I anything the

Operator

question Alliance Partners. James of The comes from Global next Molloy

James Molloy

Congrats love sort interest? of as IMUNON immunotherapy X the sort or joining will of give your to level CEO. the looking of into Or appointment to thoughts was you most the highest the you What your confidence. and vaccine Dr. sort sort which of I'd sets sort trials the Lindborg, ongoing. of when of between at get of maybe the --

to -- this X you a Could want sort at can bad about you seems going of is on what may almost little might bit -- be is data XXX? out talk data. OVATION look IMUNON? And or be maybe X aim OVATION then come good in the the be mid-'XX. behind? to So here help like coming Or make still left to the inhibitors us we is for this clinical It move there this PARP you room

Unknown Executive

array They just provide. give of beyond into technology. insight really honest, certainly Both I the hope, will and can very very exciting that questions. insights To we think goes And ultimately me, asked an what the was what your studies. approvals. between what give to And question really on trials you broad a into really interesting trials is us us be then, first, X trials these come

first very a that can the ways technology, my able approval. test can think to seek very path for directly. thing was the that's we're be that knowing me the exciting -- tangible prepared that But then beyond I the think to to is was a in we most that this we that have what So to see really used of exciting opportunities. is set we And know I can we'll that company remarks, me, as bountiful word a expand towards I

Your Yes. second -- question, me remind

PARP standard want receiving women when see stronger top look trial, in emergence, last see in And absolutely, care women these fact, the on this are and XXX, we were we emerging. from data, We certainly the to what So inhibitors any we want our specifically interim frankly, at of actually we see see that, to at fighting, treatments therapy. company, interim, in -- we effective progressing. novel of results the who

it in treatment. does way no So invalidate the

and seeing to there we're synergistic additive be that effect. fact, a appears In

to we're what's of that's part our business. just evolving So pleased see and

build that's upon made. progress to have We any

Michael H. Tardugno

also, And less represents currently PARP have about Jim, with the to patients only for neoadjuvant that positive. treatment. little let bit are the or HRD-positive genomic for patients -- that of a a or the are indicated indicated neoadjuvant And inhibitors BRCA certain add me signature, XX% they be

those in advantages is are -- so with inhibitors. patients mean patients PARP expect I very encouraging deliver inhibitors. synergistic also So some we treated indicated to is treated PARP the And to not effect for IMNN-XXX, it or who

point that's So view. of our

James Molloy

it's I PARP -- would here in be a like, thinking any trial know III Phase mid-'XX? obviously, respect? for inhibitor data, looking data waiting the the III, what that Phase look the might the presuming some And Or but good at design thoughts in again, on

Michael H. Tardugno

Yes.

subject all of a that's So discussion. -- so

for study. to well assuming going we of current not The to be of like very populations the I always -- would on groups going mean, could our any And data. be both if dependent be interesting I take. eliminate probably be X it's It of to based again, the person, -- each. probably. direction either strength very a this upon the that's to trial approach. were we'll includes But it's the the could And that -- betting I a it it's in going think stratified data.

to the results you that of designed find trials that's -- [ a study like exclude much application. you we success, outline broad of success populations benefit. companies narrow unfortunately, I develop will so We're anathema small ours. so therapeutics strategy looking to lot could to goal oncology ] the that the sometimes world individuals be who a has parts get regulatory that is percentage unfortunately, potentially much One you the to about those benefit. sometimes regulatory way of And a positive continue a of the have narrow the can But or population who so unfortunate to to

groups. makes are opportunity we the do study. it we'll betting again, that's evaluate that was a a our that both we with So on if intent-to-treat tie sure person, the that, currently I'll We'll but enrolled It if the and do making currently in sense? to being that XXX able have as to of I'm do -- population say effect to include

James Molloy

the The on an And And an side, -- trial? of I'll top filing? Indeed. vaccine when XXX be a and what's for anticipate is expectations plus you questions, Absolutely. done. the [indiscernible], couple update of XXX then line the follow-up on SARS-CoV-X started. do trial up over maybe XXX I/II IND then data Phase there getting that the from And then

Michael H. Tardugno

Yes.

or but talking in So did, MRD we XXX misspoke Avastin I ] you're Is that Yervoy you -- know if about? [ with don't combining I on we're one study. the or the

James Molloy

going Avastin notes start I my running. you in and [indiscernible] that to are your the Well, with know up I guys you [indiscernible]. combo look have a to had and

Michael H. Tardugno

I'm sorry.

in checkpoint think combination conversations that We're world a thought approach. earlier be kind we of -- in indicated inhibitor Jim. right So we this some a might might very stuck that I now, interesting conserved capital

it. as But consider a don't if very these Dr. lot to I combination. or that'd that? to of I focus for comment be like a you'd if future interesting So think Sebastien, the therapeutics, know on Anwer we

Dr. Sebastien Hazard

absolutely. Yes, No.

in active synergy I terms project this that been very is ovarian I've fully to a opportunity. looking could that think an into really and nice in help a be of cancer immunotherapy

to the an So as project will resources we Michael provided be said, get initiate. that excellent

Michael H. Tardugno

question? part repeat of your sorry, you the second I'm could

James Molloy

And burner? we preservation The then the on to Phase XXX capital is data is a come of, again, at data the out. XXX expectation, roughly, little I which anticipate back kind bit

Michael H. Tardugno

say can unequivocally. I that Yes.

a just programs deal our believe narrowed but to the of to regards concept. focus platforms we we've proof from these focus to effect have our the that of seen, narrowed we've -- about. With talked data great So immediate we've potential,

So we progress report but nature information be durability durability both vaccine we of to on we'll where expect won't that know able is the top that, line for year. we data won't the before We'll key. think -- the have is certainly the certainly We of the end have the response. the immunogenicity and

the end year. before the Yes, So of

Operator

to would remarks. conference This concludes turn over the our management any for question-and-answer to back session. I closing like

Michael H. Tardugno

much. very a that little questions bit to proud you explored for in me Let opportunity expand saying the the more doing that an and particularly thank allowing very And area finish technology of. We're we're been of has on the first by that companies. so work we're focusing us by many

the therapeutic leadership with vaccine. potentially this as think I a been able as Anwer's under we've team, Dr. support DNA unlock the a and to and potential of of management

Dr. Chairman that and very, for future exciting. I something one is this call. company. underscoring you Lindborg's is us, have choice I the the said, potential all the the our so leadership to want thank I the probably Executive for is under very of participating of technologies in as And that is of of proprietary Again,

As potential the remain our cancer the to progresses women options increases, pandemic months. excited the we're and you report committed, to in that providing ovarian we in exposure in work prepared and making coming population's to progress to

a afternoon. we forward you So and employees here IMUNON, on I Thank very and here look of the and and us all our very behalf informed we to much. wish keeping we on you -- of call, you nice safe

Operator

for concluded. now Thank has attending today's presentation. conference The you

You may now disconnect.

Imunon (IMNN) 13 May 242024 Q1 Earnings call transcript